Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Active stumbles; Peptide takes notes

Active Biotech AB thought it had found a suitable group of patients in its Phase II trials who would respond to its ETEC vaccine to treat enterotoxigenic E. coli-associated diarrhea in travelers. But following last week's failure of its Phase III trial, the company plans to pore through the

Read the full 498 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers